ENYO Pharma’s vonafexor reverses kidney decline in Alport syndrome with sustained benefit
Vonafexor reversed kidney decline in Alport syndrome patients. Find out what ENYO Pharma’s Phase 2 results could mean for FXR drugs and kidney care.
Can Alessa’s Enolen implant change how early-stage prostate cancer is treated?
Alessa’s Enolen earns FDA fast track for localized prostate cancer. Find out how this implant could redefine early-stage treatment and challenge current norms.
Is Ossium Health redefining bone marrow transplants with off-the-shelf cryopreservation?
Ossium Health’s cryopreserved bone marrow is showing early clinical success. Find out how this could disrupt allogeneic transplantation logistics.
Savara selects PANTHERx as exclusive pharmacy for MOLBREEVI amid PAP BLA review
Savara names PANTHERx as exclusive pharmacy for MOLBREEVI in autoimmune PAP. Find out what this launch model means for access, adoption, and strategy.
Can KalVista’s refill-led EKTERLY growth signal a new standard in on-demand HAE care?
KalVista’s oral HAE drug EKTERLY hit $49M in 2025 sales. Discover what strong refill demand and global expansion mean for rare disease treatment models.
MH002 enters phase 2b: Can MRM Health’s live biotherapeutic consortium redefine ulcerative colitis treatment standards?
MRM Health’s MH002 enters phase 2b for ulcerative colitis. Can this live biotherapeutic redefine immune-sparing treatment in IBD? Find out what’s at stake.
Why Aurora Therapeutics believes the FDA is ready for grouped CRISPR approvals
Can Aurora Therapeutics make CRISPR work at scale? Find out how its platform model for rare disease editing is testing biotech’s next big leap.
Can zetomipzomib move the needle in autoimmune hepatitis? What Kezar’s FDA meeting signals
Kezar is seeking FDA alignment for zetomipzomib in autoimmune hepatitis. Find out what’s at stake for trial design, safety, and strategic alternatives.
Why Biocytogen and Acepodia are betting on BsAD2Cs for next-gen cancer therapy
Biocytogen and Acepodia expand their ADC collaboration to evaluate dual-payload bispecifics. Find out how this model could reshape solid tumor therapy.
Can Clarametyx’s CMTX-101 reshape cystic fibrosis care by targeting biofilms?
Clarametyx’s CMTX-101 showed strong early signals in cystic fibrosis. Find out what this means for chronic lung infections and future bronchiectasis care.